Home > Inhibitors & Agonists > Antibiotics and Antivirals

Antibiotics and Antivirals

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC73016 OJT008 OJT008 is a small molecule Mtb. MetAP inhibitor against M. tuberculosis, has MIC50 of 0.063 µg/mL against both active and MDR Mtb.
DC73017 OSM-S-106 OSM-S-106 is a reaction hijacking inhibitor of Plasmodium falciparum asparagine tRNA synthetase (PfAsnRS), inhibits the 3D7 line of P. falciparum with IC50 of 58 nM.
DC73018 P4Q-391 P4Q-391 is an antimalarial agent with selective inhibition of the parasite's coenzyme Q cycle, inhibits mitochondrial cytochrome bc1 complex (Cyt bc1).
DC73019 SCR0911 SCR0911 is a potent malarial cytochrome bc1 inhibitor, inhibits cell growth and ATP synthesis in both the fast- and slow-growing M. smegmatis and M. bovis bacillus Calmette-Guérin, respectively.
DC73020 T-3767758 T-3767758 is a potent, proline-uncompetitive inhibitor of prolyl-tRNA synthetase (ProRS), displays good activity with EC50 of 595 nM against P. falciparum Dd2-2D4 wild-type parasites.
DC73021 TCMDC-136879 TCMDC-136879 is a cyclic acyl guanidine compound with antimalarial activity.
DC73022 TDI-8304 TDI-8304 is a highly selective, macrocyclic peptide inhibitor of malaria parasite Plasmodium falciparum proteasome (Pf20S) with IC50 of 0.06 uM, shows high potency against P. falciparum strain Pf 3D7 (EC50=0.009 uM).
DC73023 UBMC-4 UBMC-4 is a potential Trypanosoma cruzi AKT-like pleckstrin homology (PH) domain, exhibits trypanocidal effect on T. cruzi amastigotes with EC50 of 1.85 uM (0.774 ug/mL).
DC73024 WEHI-518 WEHI-518 is a small molecule inhibitor of the parasite's phosphatidylinositol kinase PfPI4KIIIB, shows EC50 of 22 nM against blood-stage P. falciparum parasites.
DC73025 WEHI-600 WEHI-600 is a potent, small molecule inhibitor of the aspartic proteases Plasmepsin X (PMX) with IC50 of 3 nM, possess potent anti-parasitic activity (P. falciparum parasite, IC50=7 nM).
DC73026 WEHI-601 WEHI-601 is a potent, small molecule inhibitor of the aspartic proteases Plasmepsin X (PMX) with IC50 of 5 nM, possess potent anti-parasitic activity (P. falciparum parasite, IC50=9 nM).
DC73027 WJM228 WJM228 (WJM-228) is a potent selective inhibitor of P. falciparum cytochrome bc1, targets the Qo site of cytochrome b (cyt b), shows potent parasite activity against P. falciparum 3D7 with EC50 of 19 nM.
DC73028 ARN1468 ARN1468 is an anti-prion, cellular active small molecule targeting SERPINA3 (ITC KD=26 uM), decreases prion accumulation and reduces PrPSc in the ScGT1 RML cell line with EC50 of 8.64 uM.
DC73029 OBR-5-340 OBR-5-340 is a potent, orally bioavailable inhibitor targeting capsid of Rhino- and Enteroviruses,exhibits broad-spectrum antiviral activity against of enteroviruses and rhinoviruses.
DC73030 AVG-388 AVG-388 is a potent, allosteric, orally efficacious inhibitor of respiratory syncytial virus (RSV) RNA synthesis, potently blocks RSV RNA-dependent RNA polymerase (RdRP) bioactivity, exhibits strong antiviral efficacy in vivo.
DC73031 JNJ-8003 JNJ-8003 is a highly potent, selective, non-nucleoside inhibitor of respiratory syncytial virus (RSV) polymerase with IC50 of 0.67 nM, shows EC50 of 0.15 nM in RSV subgenomic replicon assays.
DC73032 (S)-chlorcyclizine (S)-chlorcyclizine ((S)-CCZ) is an approved antihistamine drug that is related to dichlorcyclizine (DCCZ), inhibits SARS-CoV and SARS-CoV-2 S-mediated infection in MA104 cells with EC50 of 6.91 and 4.09 uM.
DC73033 AB-00011778 AB-00011778 is a small molecule inhibitor of SARS-CoV-2 entry and the Spike/ACE2 interaction, inhibits viral replication with EC50 of 250 nM in A549-ACE2 cells, AB-00011778 is equally effective in impairing the S/ACE2 association in the different mutants.
DC73034 AC1115 AC1115 is a potent, selective, next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, AC1115 is the active form of Olgotrelvir.
DC73035 Acriflavine Acriflavine (Acriflavin) is a topical antiseptic that found to be a potent papain-like protease (PLpro) inhibitor, inhibits SARS-CoV-2 and other betacoronaviruses.
DC73036 ALG-097111 ALG-097111 is a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease (3CLpro) with IC50 of 7 nM, without effect against human cathepsin L (IC50>10 uM).
DC73037 Cyanorona-20 Cyanorona-20 is a potent and specific SARS-CoV-2 inhibitor with very high selectivity (209- and 45-fold more potent than favipiravir and remdesivir, respectively), effectively binds to and inhibits the SARS-CoV-2 RdRp.
DC73038 D-4-77 D-4-77 is a potent, covalent peptidyl inhibitor of SARS-CoV-2 main protease (Mpro) with IC50 of 0.95 uM and antiviral EC50 of 0.49 uM.
DC73039 Difluorobenztropine Difluorobenztropine (AHN 1-055) is a direct-acting SARS-CoV-2 entry inhibitor that targets the SARS-CoV-2 spike fusion peptide domain.
DC73040 DMGA DMGA is an allosteric and covalent inhibitor of SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro) with IC50 of 9.4 uM, covalently binds with C270 of the SARS-CoV-2 PLpro.
DC73041 DS0464 DS0464 is a selective, bisubstrate competitive inhibitor SARS-CoV-2 nonstructural protein 14 (nsp14) with IC50 of 1.1 uM, also selective against 28 out of 33 RNA, DNA, and protein MTases.
DC73043 EIDD-2801 EIDD-2801 (MK-4482, Molnupiravir) is a highly potent ribonucleoside analog, and prodrug of EIDD-1931, exhibits broad-spectrum antiviral inhibitor of multiple RNA viruses including SARS-CoV-2.
DC73044 GC-14 GC-14 is a potent, selective and non-covalent non-peptide SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 0.4 uM, displays excellent selectivity over cathepsins B, F, K, L, and caspase 3 (IC50>50 uM).
DC73045 GC-373 GC373 is a potent, covalent inhibitor of SARS CoV-2 main protease (MPro) with Kd of 0.15 uM, the reactive aldehyde form of GC376.
DC73046 GC-78-HCl GC-78-HCl is a potent nonpeptide SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 0.19 uM, exhibits excellent antiviral activity (EC50=0.4 uM).

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>